EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Thalidomide in Reducing Blood Transfusion in Transfusion Dependent Thalassemia Major Patients

Javaria Rasool, Muhammad Aatif, Mussammat Zubair, Iqra Shahzad

International Journal of Drug Delivery Technology · 11.05.2026 · 16 (26s)

DOI: 10.25258/ijddt.16.26s.112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 11.05.2026. Verfasst von Javaria Rasool und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thalassemia major is a transfusion-dependent hemoglobinopathy associated with iron overload and multiple complications. Reducing the frequency of blood transfusions can improve patient outcomes and quality of life. Thalidomide, an immunomodulatory agent, has shown potential in increasing hemoglobin levels and reducing transfusion requirements.

Objectives

To evaluate the efficacy of thalidomide in reducing blood transfusions in transfusion-dependent thalassemia major patients. Study Design & Setting: A descriptive case series conducted at the Department of Pediatric Medicine, Fauji Foundation Hospital, Rawalpindi from 1st October 2025 to 1st January 2026. Methodology: Using successive non-probability sampling, 86 patients with beta thalassemia major, ranging in age from 1 to 15 years, were included in the study. These patients had received transfusions four to six times weekly for the previous two years. Patients received oral thalidomide starting with hydroxyurea and supportive treatment, starting at 1-2 mg/kg/day and increasing to 4 mg/kg/day as needed. Blood samples were collected for complete blood count and biochemical testing. We used SPSS 25.0 to analyze the data. Qualitative data were shown as percentages and frequency, whilst quantitative factors were shown as mean ± SD. Stratification was performed for age, gender, weight, duration of disease, and annual blood transfusions. A p-value less than 0.05 was deemed significant when chi-square tests were utilized.

Results

Among 86 patients, 57 (66.3%) achieved efficacy, maintaining hemoglobin ≥9 g/dL without transfusion. Males, patients with a disease duration of 5 years or less, and those having 15 transfusions or less per year had a considerably better efficacy (p = 0.000 for all). Age and weight were not significantly associated with efficacy.

Conclusion

Thalidomide is effective in reducing transfusion requirements in thalassemia major, particularly in males, patients with shorter disease duration, and those with lower annual transfusion needs.

Zitieren

APA

Rasool, J., Aatif, M., Zubair, M., & Shahzad, I. (2026). Efficacy of Thalidomide in Reducing Blood Transfusion in Transfusion Dependent Thalassemia Major Patients. International Journal of Drug Delivery Technology, 16(26s). https://doi.org/10.25258/ijddt.16.26s.112

Vancouver

Rasool J, Aatif M, Zubair M, Shahzad I. Efficacy of Thalidomide in Reducing Blood Transfusion in Transfusion Dependent Thalassemia Major Patients. International Journal of Drug Delivery Technology. 2026;16(26s). doi:10.25258/ijddt.16.26s.112

BibTeX
@article{Rasool2026,
  author = {Rasool, Javaria and Aatif, Muhammad and Zubair, Mussammat and Shahzad, Iqra},
  title = {Efficacy of Thalidomide in Reducing Blood Transfusion in Transfusion Dependent Thalassemia Major Patients},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {26s},
  doi = {10.25258/ijddt.16.26s.112}
}
Kostenlos starten →